Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the ...

The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early ...

encouraging larger follow-up studies with refined Na+/K+ ATPase inhibitors and that include clinical outcome endpoints.” Certain tumor types do not remain at their point of origin but spread ...

The study design comprised measuring the effect of the cardiotonic agent digoxin (a widely used Na+/K+ ATPase inhibitor) in reducing the size of circulating tumor cells clusters, i.e. aggregates ...